

Brilliant Violet 421™ Streptavidin

Catalog# / Size	405226 / 100 µL 405225 / 100 µg
Regulatory Status	RUO
Other Names	SAv-Brilliant Violet 421™
Description	Streptavidin binds to biotin with high affinity. Streptavidin-Brilliant Violet 421™ is useful for detecting biotinylated antibodies. The excitation of Brilliant Violet 421™ by 405 nm laser light induces a fluorescence maximum emission of 421 nm.

Product Details

Verified Reactivity	Human, Mouse, Rat, All Species
Formulation	Cat. No. 405225: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. Cat. No. 405226: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	Streptavidin was conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	405225 is bottled at 0.5 mg/ml. 405226 is bottled at 0.1 mg/ml. (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling	The solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC, ICFC - Quality tested ICC, IHC-F, IHC-P
Recommended Usage	<p>Each lot of this Streptavidin-Brilliant Violet 421™ is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the Brilliant Violet 421™ conjugation. For immunofluorescent staining, we recommend using Cat. No. 405226 at dilutions ≤ 0.015 µg in 100 µL staining volume per million cells. For applications requiring high concentration of streptavidin reagent such as tetramer labeling, we recommend using Cat. No. 405225. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>* Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.</p> <p>Learn more about Brilliant Violet™.</p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
Excitation Laser	Violet Laser (405 nm)
Application Notes	Streptavidin-Brilliant Violet 421™ is useful as a second step reagent for indirect immunofluorescent staining when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-Brilliant Violet 421™ is 340 kD and Streptavidin alone is 52 kD.
Additional Product Notes	View more applications data using this product in immunofluorescence microscopy and labeling tetramers in flow cytometry in our Scientific Poster Library.
Application References	<ol style="list-style-type: none">1. Kim G, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:1510. PubMed.2. Giltiy NV, <i>Et al.</i> 2013. <i>J. Immunol.</i> 191:2155. PubMed3. Sugiyama D, <i>et al.</i> 2013. <i>PNAS.</i> 110:17945. PubMed4. Scally SW, <i>et al.</i> 2013. <i>J. Exp Med.</i> 210:2569. PubMed
(PubMed link indicates BioLegend citation)	

5. Lyngaa R, *et al.* 2014. *Clin Cancer Res.* 20:1768. [PubMed](#)
6. Higdon LE, *et al.* 2014. *PNAS.* 111:5652. [PubMed](#)
7. Friedman RS, *et al.* 2014. *PNAS.* 111:9223. [PubMed](#)
8. van de Weijer ML, *et al.* 2014. *Nat Commun.* 5:3832. [PubMed](#)
9. Mise-Omata S, *et al.* 2014. *Int Immunol.* [PubMed](#)
10. Choo JA, *et al.* 2014. *J Virol.* 88:10613. [PubMed](#)
11. Xing YL, *et al.* 2014. *J Neurosci.* 34:14128. [PubMed](#)
12. Luetke-Eversloh M, *et al.* 2014. *PLoS Pathog.* 10:1004441. [PubMed](#)
13. Poh Cm, *et al.* 2014. *Infect Immun.* 82:4854. [PubMed](#)
14. Cabrera-Perez J, *et al.* 2015. *J Immunol.* 194:1609. [PubMed](#)
15. Lucas A, *et al.* 2015. *PLoS One.* 10:117160. [PubMed](#)
16. Krishnaswamy JK, *et al.* 2015. *PNAS.* 112:3056. [PubMed](#)
17. Rampuria P, *et al.* 2015. *Int Immunol.* 27:253. [PubMed](#)

Product Citations

1. Steines L, *et al.* 2021. *Front Immunol.* 12:657894. [PubMed](#)
2. García-Alegria E, *et al.* 2021. *STAR Protoc.* 2:100367. [PubMed](#)
3. Reyes RA, *et al.* 2021. *PLoS One.* 16:e0261656. [PubMed](#)
4. Angkasekwinai P, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0184684. [PubMed](#)
5. van Eeden C, *et al.* 2018. *Cell Rep.* 25:3123. [PubMed](#)
6. Rad S M AH, *et al.* 2020. *PLoS One.* 15:e0232915. [PubMed](#)
7. Takizawa F, *et al.* 2016. *J Immunol.* 196: 4522 - 4535. [PubMed](#)
8. Li H, *et al.* 2022. *Front Immunol.* 13:988004. [PubMed](#)
9. Chaugule S, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
10. Domingues AF, *et al.* 2020. *Elife.* 9:e51754. [PubMed](#)
11. Parra-Sánchez H, *et al.* 2019. *Viruses.* 1.153472222. [PubMed](#)
12. Miura M, *et al.* 2019. *Wellcome Open Res.* 3:105. [PubMed](#)
13. Hayashi M, *et al.* 2017. *EBioMedicine.* 15:127-136. [PubMed](#)
14. Marco Barros R, *et al.* 2016. *Cell.* 167: 203-218. [PubMed](#)
15. Xiong W, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
16. Hu W, *et al.* 2021. *Nat Immunol.* 22:1163. [PubMed](#)
17. Kato T, *et al.* 2019. *Front Immunol.* 10:2021. [PubMed](#)
18. Viborg N, *et al.* 2019. *Oncoimmunology.* 8:e1663107. [PubMed](#)
19. Xing Y, *et al.* 2014. *J Neurosci.* 34:14128. [PubMed](#)
20. Sei J, *et al.* 2016. *PLoS One.* 11: 0152192. [PubMed](#)
21. Li H, *et al.* 2016. *J Immunol.* 196: 4064 - 4074. [PubMed](#)
22. Sage P, *et al.* 2016. *Nat Immunol.* 17:1436-1446. [PubMed](#)
23. Poon MML, *et al.* 2021. *Sci Immunol.* 6:eabi9105. [PubMed](#)
24. Krishack PA, *et al.* 2019. *JCI Insight.* 4:6. [PubMed](#)
25. Mitra T, *et al.* 2017. *Vaccine.* 10.1016/j.vaccine.2017.06.035. [PubMed](#)
26. Trivedi S, *et al.* 2015. *Vaccine.* 33: 7315-7327. [PubMed](#)
27. Sugiyama D, *et al.* 2013. *Proc Natl Acad Sci U S A.* 110:17945. [PubMed](#)
28. Giltiay N, *et al.* 2013. *J Immunol.* 191:2155. [PubMed](#)
29. Li T, *et al.* 2022. *Int J Infect Dis.* 122:874. [PubMed](#)
30. Petursdottir D, *et al.* 2017. *Front Immunol.* . 10.3389/fimmu.2017.01699. [PubMed](#)
31. Zhao M, *et al.* 2019. *Cell Rep.* 26:652. [PubMed](#)
32. Fukushima T, *et al.* 2019. *Cell Rep.* 29:4144. [PubMed](#)
33. Wu J, *et al.* 2020. *Sci Adv.* 6:eaba3458. [PubMed](#)
34. Nakagawa T, *et al.* 2021. *Cell Rep.* 37:109875. [PubMed](#)
35. Gaudette BT, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
36. Fachi JL, *et al.* 2020. *J Exp Med.* 217:00:00. [PubMed](#)
37. Im S, *et al.* 2016. *Nature.* 537:417-421. [PubMed](#)
38. Poh C, *et al.* 2014. *Infect Immun.* 82:4854. [PubMed](#)
39. Cai D, *et al.* 2021. *Front Mol Biosci.* 8:686803. [PubMed](#)
40. Zhang R, *et al.* 2021. *MAbs.* 13:1904546. [PubMed](#)
41. Neumann B, *et al.* 2019. *Cell Stem Cell.* 25:473. [PubMed](#)
42. Xu L *et al.* 2017. *Immunity.* 47(3):538-551 . [PubMed](#)
43. Wilmore JR *et al.* 2018. *Cell host & microbe.* 23(3):302-311 . [PubMed](#)
44. Koay H, *et al.* 2016. *Nat Immunol.* 10.1038/ni.3565. [PubMed](#)
45. Lucas A, *et al.* 2015. *PLoS One.* 10:117160. [PubMed](#)
46. Glaros V, *et al.* 2021. *Immunity.* 54:2005. [PubMed](#)
47. Taguchi A, *et al.* 2017. *Cell Stem Cell.* 21:730. [PubMed](#)
48. Hansen UK, *et al.* 2020. *Front Immunol.* 11:373. [PubMed](#)
49. Krishnaswamy J, *et al.* 2015. *Proc Natl Acad Sci U S A.* 112:3056. [PubMed](#)
50. Cameron G, *et al.* 2015. *J Immunol.* 195: 4604 - 4614. [PubMed](#)
51. Rowan A, *et al.* 2016. *PLoS Pathog.* 12:e1006030. [PubMed](#)
52. Lin C, *et al.* 2022. *Nat Commun.* 13:6869. [PubMed](#)
53. Tarke A, *et al.* 2022. *Cell.* 185:847. [PubMed](#)
54. Bähr A, *et al.* 2016. *PLoS One.* 11: 0155676. [PubMed](#)
55. Xu Z, *et al.* 2016. *Nat Commun.* 7:10728. [PubMed](#)
56. Liu B, *et al.* 2015. *J Immunol.* 194:3583. [PubMed](#)
57. Alameh MG, *et al.* 2021. *Immunity.* 54:2877. [PubMed](#)
58. Cavazzoni CB, *et al.* 2022. *Cell Rep.* 38:110399. [PubMed](#)
59. Nosho S, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
60. Delacher M, *et al.* 2020. *Immunity.* 52:295. [PubMed](#)
61. Roberts E, *et al.* 2016. *PLoS One.* 11:e0168488. [PubMed](#)
62. Elayeb R, *et al.* 2016. *Haematologica.* 101: 209 - 218. [PubMed](#)
63. Cuenca M, *et al.* 2016. *J Immunol.* 196: 726 - 737. [PubMed](#)
64. Weijer M, *et al.* 2014. *Nat Commun.* 5:3832. [PubMed](#)

65. Borroto A, *et al.* 2022. *Front Immunol.* 13:799919. [PubMed](#)
66. Song R, *et al.* 2022. *Front Immunol.* 13:1028246. [PubMed](#)
67. Xi-Zhi J Guo *et al.* 2018. *Immunity.* 49(3):531-544 . [PubMed](#)
68. Parra-Sánchez H, *et al.* 2018. *Mol Immunol.* 96:1. [PubMed](#)
69. Sanjo H, *et al.* 2015. *PLoS One.* 10: 0128761. [PubMed](#)
70. Ma X, *et al.* 2020. *Immunity.* 53:1315. [PubMed](#)
71. Hasegawa T, *et al.* 2020. *Sci Rep.* 10:13480. [PubMed](#)
72. Blomberg R, *et al.* 2019. *Matrix Biol.* 83:60. [PubMed](#)
73. Yang E, *et al.* 2016. *J Immunol.* 197: 934 - 941. [PubMed](#)
74. Salzberger W, *et al.* 2015. *PLoS One.* 10: 0145324. [PubMed](#)
75. Tsuzuki S, *et al.* 2015. *Int Immunol.* 10.1093/intimm/dxv058. [PubMed](#)
76. Cabrera-Perez C, *et al.* 2015. *J Immunol.* 194:1609-20. [PubMed](#)
77. Scally S, *et al.* 2013. *J Exp Med.* 210:2569. [PubMed](#)
78. Wang Z, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
79. Guelen L, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
80. Cirelli KM *et al.* 2019. *Cell.* 177(5):1153-1171 . [PubMed](#)
81. Wen J, *et al.* 2020. *Cell Rep.* 31:107566. [PubMed](#)
82. Claudepierre M, *et al.* 2014. *J Virol.* 88:5242. [PubMed](#)
83. Friedman R, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:9223. [PubMed](#)
84. Lundell A, *et al.* 2017. *Sci Rep.* 7:39904. [PubMed](#)
85. Fra-Bido S, *et al.* 2021. *STAR Protocols.* 2(3):100499. [PubMed](#)
86. Tulyeu J, *et al.* 2021. *Curr Protoc.* 1:e283. [PubMed](#)
87. Lederer K, *et al.* 2022. *Cell.* . [PubMed](#)
88. Müller TR, *et al.* 2021. *Cell Rep Med.* 2:100374. [PubMed](#)
89. Dan JM, *et al.* 2021. *Science.* :371. [PubMed](#)
90. Mise-Omata S, *et al.* 2014. *Int Immunol.* 26:607. [PubMed](#)
91. Fries CN, *et al.* 2021. *Sci Rep.* 11:14494. [PubMed](#)
92. An X, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0181904. [PubMed](#)
93. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
94. Luetke-Eversloh M, *et al.* 2014. *PLoS Pathog.* 10:1004441. [PubMed](#)
95. Lang P 2015. *Int Immunol.* 27:253. [PubMed](#)
96. Younis R, *et al.* 2016. *J Immunol.* 196: 1419 - 1429. [PubMed](#)
97. Mchedlidze T, *et al.* 2016. *Mucosal Immunol.* 10.1038/mi.2016.20. [PubMed](#)
98. Zhu L, *et al.* 2016. *J Cell Sci.* 129: 4238 - 4251. [PubMed](#)
99. Chryplewicz A, *et al.* 2022. *Cancer Cell.* 40:1111. [PubMed](#)
100. Wells DK, *et al.* 2020. *Cell.* 183:818. [PubMed](#)
101. Clement RL, *et al.* 2019. *Nat Immunol.* 20:1360. [PubMed](#)
102. Kim JM, *et al.* 2020. *Nat Commun.* 11:2289. [PubMed](#)
103. Silva HM, *et al.* 2019. *J Exp Med.* 216:786. [PubMed](#)
104. Lederer K, *et al.* 2020. *Immunity.* 53(6):1281-1295.e5. [PubMed](#)
105. Mackroth M, *et al.* 2016. *PLoS Pathog.* 12:e1005909. [PubMed](#)
106. Xiao C, *et al.* 2021. *STAR Protoc.* 2:100789. [PubMed](#)
107. Rodrigues KA, *et al.* 2021. *Sci Adv.* 7:eabj6538. [PubMed](#)
108. Mesin L, *et al.* 2020. *Cell.* 180(1):92-106.e11.. [PubMed](#)
109. Mahmoudi S, *et al.* 2019. *Nature.* 574:553. [PubMed](#)
110. Lyngaa R, *et al.* 2014. *Clin Cancer Res.* 20:1768. [PubMed](#)
111. Choo J, *et al.* 2014. *J Virol.* 88:10613. [PubMed](#)
112. Cho A, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
113. Brunk F, *et al.* 2021. *Eur J Immunol.* 51:2651. [PubMed](#)
114. Giri T, *et al.* 2022. *Heliyon.* 8:e09407. [PubMed](#)
115. Binnewies M, *et al.* 2019. *Cell.* 177:556. [PubMed](#)
116. Higdon L, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:5652. [PubMed](#)
117. Kim G, *et al.* 2013. *J Immunol.* 190:1510. [PubMed](#)


Antigen Details

Gene ID NA

Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Product Data



Human peripheral blood lymphocytes were stained with biotinylated CD3 (filled histogram) or mouse IgG1 isotype control (open histogram), followed with SAV-Brilliant Violet 421™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587